Invention Grant
- Patent Title: Compounds for use as therapeutic agents affecting P53 expression and/or activity
-
Application No.: US15840847Application Date: 2017-12-13
-
Publication No.: US10538485B2Publication Date: 2020-01-21
- Inventor: Didier Scherrer , Jamal Tazi , Romain Najman , Florence Mahuteau , Pierre Roux
- Applicant: ABIVAX , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , INSTITUT CURIE , UNIVERSITE DE MONTPELLIER
- Applicant Address: FR Paris FR Paris FR Paris FR Montipellier
- Assignee: ABIVAX,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE,INSTITUT CURIE,UNIVERSITE DE MONTPELLIER
- Current Assignee: ABIVAX,CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE,INSTITUT CURIE,UNIVERSITE DE MONTPELLIER
- Current Assignee Address: FR Paris FR Paris FR Paris FR Montipellier
- Agency: Oliff PLC
- Priority: EP11305385 20110401
- Main IPC: C07C237/30
- IPC: C07C237/30 ; A61K31/166 ; A61K31/167 ; A61K31/4164 ; A61K31/417 ; A61K31/4192 ; A61K31/4409 ; A61K31/4439 ; A61K31/4545 ; A61K31/495 ; A61K31/496 ; A61K31/5377 ; C07D213/36 ; C07D233/64 ; C07D249/06 ; C07D401/12 ; C07D213/38 ; C07D233/61

Abstract:
The present disclosure relates to compound (I) wherein R1 and R2 independently represent a hydrogen atom, a (C1-C4)alkoxy group, a fluoro(C1-C4)alkoxy group, a hydroxyl group, a benzyloxy group, a di(C1-C4)alkylamino group, a pyridyl-vinyl group, a pyrimidinyl-vinyl group, a styryl group, or a —NHCOphenyl group; R3, R4 and R5 independently represent a hydrogen atom, a (C1-C4)alkyl group, a CONHR6 group, a —CONR7R8 group, a —SO2NHR6 group, or a heteroaryl group optionally substituted by a halogen atom, a —(CH2)nNR7R8 group or a hydroxy(C1-C4)alkyl group; R6 represents a hydrogen atom, a —(CHR9)m(CH2)nNR7R8 group or a (C1-C6)alkyl group optionally substituted by a hydroxyl group; or anyone of its pharmaceutically acceptable salt, for use in a method for preventing, inhibiting or treating a disease in a patient suffering thereof, said disease involving a deregulated p53. Some of said compounds are new and also form part of the disclosure.
Public/Granted literature
- US20180127353A1 COMPOUNDS FOR USE AS THERAPEUTIC AGENTS AFFECTING P53 EXPRESSION AND/OR ACTIVITY Public/Granted day:2018-05-10
Information query